Zacks Research Brokers Boost Earnings Estimates for Amarin

Amarin Corporation PLC (NASDAQ:AMRN - Free Report) - Equities researchers at Zacks Research upped their Q3 2025 earnings per share estimates for shares of Amarin in a research note issued on Wednesday, June 25th. Zacks Research analyst R. Department now expects that the biopharmaceutical company will earn ($0.60) per share for the quarter, up from their prior forecast of ($0.74). The consensus estimate for Amarin's current full-year earnings is ($0.15) per share. Zacks Research also issued estimates for Amarin's Q4 2025 earnings at ($1.01) EPS, Q1 2026 earnings at ($0.49) EPS, Q2 2026 earnings at ($0.04) EPS, Q3 2026 earnings at ($0.35) EPS, Q4 2026 earnings at ($0.71) EPS, FY2026 earnings at ($1.59) EPS, Q1 2027 earnings at ($0.07) EPS and FY2027 earnings at ($0.67) EPS.

Several other brokerages have also recently commented on AMRN. The Goldman Sachs Group raised their target price on shares of Amarin from $7.00 to $12.00 and gave the stock a "sell" rating in a report on Wednesday, June 25th. Wall Street Zen raised Amarin from a "sell" rating to a "hold" rating in a research report on Thursday, May 8th.

Amarin Price Performance

Amarin stock traded up $0.53 during midday trading on Friday, hitting $16.24. The company's stock had a trading volume of 142,378 shares, compared to its average volume of 98,179. The company has a market cap of $336.33 million, a price-to-earnings ratio of -4.46 and a beta of 0.71. Amarin has a 1-year low of $7.08 and a 1-year high of $17.18. The company has a 50-day moving average price of $11.79 and a two-hundred day moving average price of $10.70.

Amarin (NASDAQ:AMRN - Get Free Report) last announced its earnings results on Wednesday, May 7th. The biopharmaceutical company reported ($0.04) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.06) by $0.02. Amarin had a negative net margin of 41.07% and a negative return on equity of 17.21%.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of AMRN. Acadian Asset Management LLC grew its stake in Amarin by 112.3% during the first quarter. Acadian Asset Management LLC now owns 3,791,515 shares of the biopharmaceutical company's stock worth $1,685,000 after buying an additional 2,005,713 shares in the last quarter. Jones Financial Companies Lllp lifted its holdings in shares of Amarin by 449,522.1% during the 1st quarter. Jones Financial Companies Lllp now owns 1,811,977 shares of the biopharmaceutical company's stock worth $815,000 after acquiring an additional 1,811,574 shares during the period. AXA S.A. acquired a new stake in shares of Amarin during the 4th quarter worth approximately $480,000. Raymond James Financial Inc. bought a new position in Amarin in the fourth quarter valued at approximately $343,000. Finally, Stonepine Capital Management LLC increased its stake in Amarin by 470.3% in the first quarter. Stonepine Capital Management LLC now owns 651,614 shares of the biopharmaceutical company's stock valued at $293,000 after acquiring an additional 537,357 shares during the last quarter. Institutional investors and hedge funds own 22.25% of the company's stock.

About Amarin

Amarin Corporation plc, a pharmaceutical company, engages in the development and commercialization of therapeutics for the treatment of cardiovascular diseases in the United States, European countries, Canada, Lebanon, and the United Arab Emirates. The company offers VASCEPA, a prescription-only omega-3 fatty acid product, used as an adjunct to diet for reducing triglyceride levels in adult patients with severe hypertriglyceridemia.